CliffBio
small molecule

BUDESONIDE

BUDESONIDE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUDESONIDE
Active ingredientBUDESONIDE
Strength0.032MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalNovember 2015
Marketing statusOTC

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.